



EXACERBATION ASSESSMENT FORM (VISIT 1)

ID NUMBER:	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------

FORM CODE: EAF
VERSION: 2.0 05/14/2019

Event: _____

0a) Date of Collection: / /

0b) Staff Code:

Instructions: This form should be completed during the participant's Exacerbation Substudy Visit 1. Please note that items 1 and 2 are populated based on the TEA data collection form entry.

1) Date of phone contact / /

2) Date symptoms first started / /

3) Was the participant able to present to the clinical center within seven days of exacerbation event onset?

No₀ → **End Form**

Yes₁

4) Are the exacerbation event symptoms ongoing?

No₀

Yes₁ → **Go to 5**

4a) If No, when did the exacerbation event symptoms stop? / /

4b) Has it been more than 48 hours since the symptoms stopped?

No₀

Yes₁ → **End Form; participant does not meet inclusion criteria for exacerbation visit 1.**

Review of Symptoms

5) Since the start of your exacerbation symptoms, have you experienced an increase and/or change in the following **major** symptoms for at least two or more consecutive days?

No₀ Yes₁

5a) Shortness of breath

5b) Change in sputum discharge color (yellow/green)

5c) Sputum volume

ID NUMBER:										
------------	--	--	--	--	--	--	--	--	--	--

6) Since the start of your exacerbation symptoms, have you experienced an increase in the following **minor** symptoms for at least two or more consecutive days?

No₀ Yes₁

- | | | |
|---------------------|--------------------------|--------------------------|
| 6a) Nasal discharge | <input type="checkbox"/> | <input type="checkbox"/> |
| 6b) Wheeze | <input type="checkbox"/> | <input type="checkbox"/> |
| 6c) Sore throat | <input type="checkbox"/> | <input type="checkbox"/> |
| 6d) Cough | <input type="checkbox"/> | <input type="checkbox"/> |
| 6e) Fever | <input type="checkbox"/> | <input type="checkbox"/> |

Physical Assessment

7) Do you suspect any conditions other than or in addition to Acute Exacerbation COPD (AECOPD)?

No₀ → **Go to 8**

Yes₁

If Yes, please specify the conditions that were ruled out.

- 7a) Pneumonia
 7b) Acute Respiratory Failure
 7c) Other

7c1) If Other, please specify: _____

Physical Assessment / Vital Signs

- 8) Body weight . kg
 9) Body Mass Index (BMI) . kg/m²

Note: The BMI value will automatically calculate in the DMS using height from Visit 5 ANT2.

- 10) Temperature . ° C
 11) Respiratory Rate breaths/min
 12) Heart Rate beats/min
 13) Systolic Blood Pressure mm Hg
 14) Diastolic Blood Pressure mm Hg

ID NUMBER:										
------------	--	--	--	--	--	--	--	--	--	--

Event: _____

15) O2 saturation

<input type="text"/>	<input type="text"/>	<input type="text"/>	%
----------------------	----------------------	----------------------	---

15a) Do you currently use supplemental oxygen?

No₀ → **Go to 16**

Yes₁

15a1) Is this a newly prescribed oxygen therapy?

No₀

Yes₁

15a2) Is it an increase to your usual oxygen therapy?

No₀

Yes₁

16) Was a chest examination conducted?

No₀ → **Go to 17**

Yes₁

If Yes, which of the following were present during the chest examination?

16a) Wheezes

No₀ Yes₁

<input type="checkbox"/>	<input type="checkbox"/>
--------------------------	--------------------------

16b) Crackles/ rales

<input type="checkbox"/>	<input type="checkbox"/>
--------------------------	--------------------------

16c) Rhonchi sounds

<input type="checkbox"/>	<input type="checkbox"/>
--------------------------	--------------------------

16d) Diminished breath sounds

<input type="checkbox"/>	<input type="checkbox"/>
--------------------------	--------------------------

16e) Increased respiratory rate and/ or labored breathing

<input type="checkbox"/>	<input type="checkbox"/>
--------------------------	--------------------------

Exacerbation Event Determination

*Definition: A probable exacerbation event is defined as an increase in two or more major symptoms **or** one major symptom and two minor symptoms.*

17) Is this a probable exacerbation event based on the above definition?

No₀ → **Go to 18**

Yes₁

17a) If Yes, what is the event duration to date?

Less than 1 day₁

1-2 days₂

3-5 days₃

1 week₄

More than 1 week₅

17b) Suspected cause (etiology)

Infection₁

Weather₂

Treatment non-compliance₃

Unknown₄

ID NUMBER:																				
------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Exacerbation Event Treatment

18) Was the participant's clinical treatment or medication(s) changed?

- No₀ → **Go to 19**
- Yes₁

If Yes, Complete items 18a-18g.

18a) Antibiotics

- No₀ → **Go to 18b**
- Yes₁

18a1) If Yes, please specify: _____

18a2) Number of days prescribed:

18b) Oral glucocorticosteroids

- No₀ → **Go to 18c**
- Yes₁

18b1) Number of days prescribed:

18c) New inhaled glucocorticosteroid

- No₀ → **Go to 18d**
- Yes₁

18c1) Number of days prescribed:

18d) Increased inhaled glucocorticosteroid dosage

- No₀ → **Go to 18e**
- Yes₁

18d1) Number of days prescribed:

18e) Methylxathines (new)

- No₀ → **Go to 18f**
- Yes₁

18e1) Number of days prescribed:

18f) β_2 -agonists (short-acting) (new or increased)

- No₀ → **Go to 18g**
- Yes₁

18f1) Number of days prescribed:

ID NUMBER:																			
------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

18g) Other significant clinical treatments or medications

No₀ → **Go to 19**

Yes₁

18g1) If Yes, please specify: _____

18g1a) Number of days prescribed:

18g2) If Yes, please specify: _____

18g2a) Number of days prescribed:

18g3) If Yes, please specify: _____

18g3a) Number of days prescribed:

18g4) If Yes, please specify: _____

18g4a) Number of days prescribed:

19) If the participant meets criteria for sputum induction, do you support him/her proceeding to sputum induction?

No₀

Yes₁

END OF FORM